Albireo Pharma, Inc.: Italian Medicines Agency Approves Reimbursed Access to Bylvay (odevixibat) For Patients with All PFIC Types
Positive Agenzia Italiana del Farmaco (AIFA) decision provides reimbursed access to the first medicine available for the treatment of all types of PFIC, a rare and devastating disorder that affects
Source: finanznachrichten.de